Related Experiment Video
Updated: May 31, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime
Jose A Bazan1, Stanley I Martin, Kenneth M Kaye
1Division of Infectious Diseases, The Ohio State University Medical Center, N1129 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210, USA.
Abstract:
This article reviews the new beta-lactam (β-lactam) antibiotics doripenem, ceftobiprole, and ceftaroline. It covers pharmacokinetic and pharmacodynamic properties, dosing, in vitro activities, safety, and clinical trial results. Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. Ceftaroline has received FDA approval for the treatment of skin and soft tissue infections and community acquired pneumonia. Ceftobiprole has not received FDA approval. The article also reviews recent data suggesting increased overall mortality with Cefepime (Maxipime) use compared with other beta-lactam antibiotics and the potential risk for neurotoxicity in the setting of renal failure.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Mechanism of Antibiotic Resistance in MRSA
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Clinical Significance of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Bacterial DNA Synthesis
